KAVIGALE Trademark

Trademark Overview

On Tuesday, December 5, 2023, a trademark application was filed for KAVIGALE with the United States Patent and Trademark Office. The USPTO has given the KAVIGALE trademark a serial number of 98299262. The federal status of this trademark filing is EX PARTE APPEAL PENDING as of Thursday, January 9, 2025. This trademark is owned by AstraZeneca UK Limited. The KAVIGALE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances, namely antibodies for neutralizing viruses for medical purposes
kavigale

General Information

Serial Number98299262
Word MarkKAVIGALE
Filing DateTuesday, December 5, 2023
Status760 - EX PARTE APPEAL PENDING
Status DateThursday, January 9, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances, namely antibodies for neutralizing viruses for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, December 5, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAstraZeneca UK Limited
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge CB20AA
GB

Trademark Events

Event DateEvent Description
Tuesday, December 5, 2023NEW APPLICATION ENTERED
Thursday, February 29, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 20, 2024ASSIGNED TO EXAMINER
Sunday, June 23, 2024NON-FINAL ACTION E-MAILED
Tuesday, August 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 27, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, June 23, 2024NON-FINAL ACTION WRITTEN
Sunday, June 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, October 7, 2024SUSPENSION LETTER WRITTEN
Monday, October 7, 2024LETTER OF SUSPENSION E-MAILED
Monday, October 7, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, October 31, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 31, 2024TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, January 3, 2025FINAL REFUSAL E-MAILED
Friday, January 3, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Friday, January 3, 2025FINAL REFUSAL WRITTEN
Thursday, January 9, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Thursday, January 9, 2025EXPARTE APPEAL RECEIVED AT TTAB
Thursday, January 9, 2025EX PARTE APPEAL-INSTITUTED
Thursday, January 9, 2025JURISDICTION RESTORED TO EXAMINING ATTORNEY

Related Keywords

kavigale viruses medical purposes neutralizing antibodies preparations substances namely pharmaceutical